Russell Investments Group Ltd. increased its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 50.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,518 shares of the life sciences company’s stock after acquiring an additional 81,358 shares during the period. Russell Investments Group Ltd. owned about 0.28% of Integra Lifesciences worth $15,903,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zeke Capital Advisors LLC acquired a new position in Integra Lifesciences during the 2nd quarter worth about $204,000. We Are One Seven LLC acquired a new stake in Integra Lifesciences in the 3rd quarter valued at about $211,000. Eagle Boston Investment Management Inc. acquired a new stake in Integra Lifesciences in the 2nd quarter valued at about $223,000. World Asset Management Inc acquired a new stake in Integra Lifesciences in the 2nd quarter valued at about $261,000. Finally, LS Investment Advisors LLC raised its position in Integra Lifesciences by 99.3% in the 2nd quarter. LS Investment Advisors LLC now owns 4,276 shares of the life sciences company’s stock valued at $275,000 after purchasing an additional 2,130 shares in the last quarter. 84.82% of the stock is currently owned by hedge funds and other institutional investors.
In other Integra Lifesciences news, Director Barbara B. Hill acquired 3,705 shares of the company’s stock in a transaction dated Monday, November 5th. The shares were acquired at an average price of $53.90 per share, for a total transaction of $199,699.50. Following the acquisition, the director now owns 63,381 shares in the company, valued at approximately $3,416,235.90. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Richard E. Caruso sold 46,676 shares of the stock in a transaction dated Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total value of $2,949,456.44. Following the completion of the transaction, the insider now owns 134,134 shares in the company, valued at approximately $8,475,927.46. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.
A number of equities research analysts have issued reports on the company. Oppenheimer reaffirmed a “buy” rating and issued a $70.00 price target on shares of Integra Lifesciences in a research report on Wednesday, October 31st. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $59.00 price target on shares of Integra Lifesciences in a research report on Wednesday, July 25th. JMP Securities reduced their price target on Integra Lifesciences from $66.00 to $62.00 and set a “market outperform” rating on the stock in a research report on Friday, November 2nd. BidaskClub lowered Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, July 27th. Finally, Zacks Investment Research lowered Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 25th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $61.92.
IART opened at $55.11 on Friday. Integra Lifesciences Holdings Corp has a one year low of $45.96 and a one year high of $67.50. The stock has a market capitalization of $4.80 billion, a PE ratio of 23.40, a price-to-earnings-growth ratio of 1.75 and a beta of 0.76. The company has a current ratio of 3.20, a quick ratio of 2.08 and a debt-to-equity ratio of 1.04.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, meeting analysts’ consensus estimates of $0.59. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The business had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. During the same quarter in the prior year, the business posted $0.45 EPS. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, research analysts expect that Integra Lifesciences Holdings Corp will post 2.39 earnings per share for the current year.
WARNING: “Russell Investments Group Ltd. Boosts Position in Integra Lifesciences Holdings Corp (IART)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/11/10/russell-investments-group-ltd-boosts-position-in-integra-lifesciences-holdings-corp-iart.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: Analyzing a company’s cash flow statement
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.